Pipeline

Overview of the rilparencel clinical program

ProKidney’s clinical development program is focused on patients with advanced CKD and diabetes who are at high risk of kidney failure. There are over 1 million people in the U.S. with Stage 3b/4 CKD and diabetes seeking better therapeutic options to prevent or delay the need for dialysis.
ProKidney Pipeline graphic updated on 2026JAN13
  • Preclin
  • IND
  • Ph 1
  • Ph 2
  • Ph 3
  • Approv
  • Preclinical
  • IND
  • Phase 1
  • Phase 2
  • Phase 3
  • Approval

REACT®/DKD

Diabetes Type II – Prevent/Delay CKD 3/4 

(20-50 ml/min/1.73m2, N=81)
Fully Enrolled

Diabetes Type II – Prevent/Delay CKD 3/4

(20-50 ml/min/1.73m2, N=1,200)
Enrolling in US

Diabetes Type II –
Delay CKD 4/5 

(14-20 ml/min/1.73m2, N=10)
Trial completed

Diabetes Repeat Dose Prevent/Delay CKD 3/4† 

(20-50 ml/min/1.73m2, N=50‡)
enrollment completed
  • Preclinical
  • IND
  • Phase 1
  • Phase 2
  • Phase 3
  • Approval

REACT®/CAKUT

Congenital Anomalies – Prevent/Delay N=15

trial completed

Footnotes:

† injecting both kidneys w/ redose trigger

‡ Increased from 30 as indicated in Proxy Amendment No. 1, page 289

Preliminary Safety Profile

To date, rilparencel appears to be well tolerated in patients injected, and no adverse events related to rilparencel have been observed. The rilparencel safety profile will continue to be closely monitored in ongoing clinical trials.

REGEN-007